Spear, B. B., Heath-Chiozzi, M. & Huff, J. Clinical application of pharmacogenetics. Trends Mol. Med. 7, 201–204 (2001).
Lazarou, J., Pomeranz, B. H. & Corey, P. N. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 279, 1200–1205 (1998).
Pirmohamed, M. et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 329, 15–19 (2004).
Feitosa Ramos, S. et al. Adverse drug reactions to anti-infectives in hospitalized children: a multicenter study in Brazil. J. Pediatr. Infect. Dis. Soc. 12, 76–82 (2023).
Jiang, H. et al. Adverse drug reactions and correlations with drug-drug interactions: a retrospective study of reports from 2011 to 2020. Front. Pharm. 13, 923939 (2022).
Zhang, Y. et al. Emergency hospitalizations for adverse drug events in China: clinical pharmacists’ approach to assessment and categorization. Pharmacoepidemiol. Drug Saf. 30, 636–643 (2021).
Konig, I. R., Fuchs, O., Hansen, G., von Mutius, E. & Kopp, M. V. What is precision medicine? Eur. Respir. J. 50, 1700391 (2017).
Ramaswami, R., Bayer, R. & Galea, S. Precision medicine from a public health perspective. Annu. Rev. Public Health 39, 153–168 (2018).
Prasad, R. B. & Groop, L. Precision medicine in type 2 diabetes. J. Intern. Med. 285, 40–48 (2019).
Buitelaar, J. et al. Toward precision medicine in ADHD. Front. Behav. Neurosci. 16, 900981 (2022).
Ahmed, S., Zhou, Z., Zhou, J. & Chen, S. Q. Pharmacogenomics of drug metabolizing enzymes and transporters: relevance to precision medicine. Genom. Proteom. Bioinforma. 14, 298–313 (2016).
Clarke, J. D. & Cherrington, N. J. Nonalcoholic steatohepatitis in precision medicine: unraveling the factors that contribute to individual variability. Pharm. Ther. 151, 99–106 (2015).
Zhou, Y., Tremmel, R., Schaeffeler, E., Schwab, M. & Lauschke, V. M. Challenges and opportunities associated with rare-variant pharmacogenomics. Trends Pharm. Sci. 43, 852–865 (2022).
Chang, W. C., Tanoshima, R., Ross, C. J. D. & Carleton, B. C. Challenges and opportunities in implementing pharmacogenetic testing in clinical settings. Annu. Rev. Pharm. Toxicol. 61, 65–84 (2021).
Johnson, J. A. & Cavallari, L. H. Pharmacogenetics and cardiovascular disease-implications for personalized medicine. Pharm. Rev. 65, 987–1009 (2013).
Limdi, N. A. et al. Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. Blood 115, 3827–3834 (2010).
Davies, S. M. et al. Pharmacogenetics of minimal residual disease response in children with B-precursor acute lymphoblastic leukemia: a report from the Children’s Oncology Group. Blood 111, 2984–2990 (2008).
Roses, A. D. Pharmacogenetics in drug discovery and development: a translational perspective. Nat. Rev. Drug Discov. 7, 807–817 (2008).
Swen, J. J. et al. A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study. Lancet 401, 347–356 (2023).
Haidar, C. E., Crews, K. R., Hoffman, J. M., Relling, M. V. & Caudle, K. E. Advancing pharmacogenomics from single-gene to preemptive testing. Annu Rev. Genom. Hum. Genet 23, 449–473 (2022).
Lavertu, A. et al. Pharmacogenomics and big genomic data: from lab to clinic and back again. Hum. Mol. Genet 27, R72–R78 (2018).
Weinshilboum, R. M. & Wang, L. Pharmacogenomics: precision medicine and drug response. Mayo Clin. Proc. 92, 1711–1722 (2017).
Roden, D. M. et al. Pharmacogenomics: challenges and opportunities. Ann. Intern. Med. 145, 749–757 (2006).
Eichelbaum, M., Ingelman-Sundberg, M. & Evans, W. E. Pharmacogenomics and individualized drug therapy. Annu. Rev. Med. 57, 119–137 (2006).
Evans, W. E. & Johnson, J. A. Pharmacogenomics: the inherited basis for interindividual differences in drug response. Annu Rev. Genom. Hum. Genet 2, 9–39 (2001).
Pirmohamed, M. Pharmacogenomics: current status and future perspectives. Nat. Rev. Genet 24, 350–362 (2023).
Kalow, W., Tang, B. K. & Endrenyi, L. Hypothesis: comparisons of inter- and intra-individual variations can substitute for twin studies in drug research. Pharmacogenetics 8, 283–289 (1998).
Lindell, A. E., Zimmermann-Kogadeeva, M. & Patil, K. R. Multimodal interactions of drugs, natural compounds and pollutants with the gut microbiota. Nat. Rev. Microbiol. 20, 431–443 (2022).
Nie, P. et al. Gut microbiome interventions in human health and diseases. Med. Res. Rev. 39, 2286–2313 (2019).
Hou, K. et al. Microbiota in health and diseases. Signal Transduct. Target Ther. 7, 135 (2022).
Steiner, H. E. et al. Role of the gut microbiome in cardiovascular drug response: the potential for clinical application. Pharmacotherapy 42, 165–176 (2022).
Zhou, C. B., Zhou, Y. L. & Fang, J. Y. Gut microbiota in cancer immune response and immunotherapy. Trends Cancer 7, 647–660 (2021).
Roviello, G., Iannone, L. F., Bersanelli, M., Mini, E. & Catalano, M. The gut microbiome and efficacy of cancer immunotherapy. Pharm. Ther. 231, 107973 (2022).
Lee, K. A. et al. Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma. Nat. Med. 28, 535–544 (2022).
Scepanovic, P. et al. A comprehensive assessment of demographic, environmental, and host genetic associations with gut microbiome diversity in healthy individuals. Microbiome 7, 130 (2019).
Zheng, P. et al. Gut microbial signatures can discriminate unipolar from bipolar depression. Adv. Sci. (Weinh.) 7, 1902862 (2020).
Vinje, S., Stroes, E., Nieuwdorp, M. & Hazen, S. L. The gut microbiome as novel cardio-metabolic target: the time has come! Eur. Heart J. 35, 883–887 (2014).
Wei, M. Y. et al. The microbiota and microbiome in pancreatic cancer: more influential than expected. Mol. Cancer 18, 97 (2019).
Robertson, R. C. et al. Maternal omega-3 fatty acids regulate offspring obesity through persistent modulation of gut microbiota. Microbiome 6, 95 (2018).
Gill, S. R. et al. Metagenomic analysis of the human distal gut microbiome. Science 312, 1355–1359 (2006).
Qin, J. et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 464, 59–65 (2010).
Zimmermann, M., Zimmermann-Kogadeeva, M., Wegmann, R. & Goodman, A. L. Mapping human microbiome drug metabolism by gut bacteria and their genes. Nature 570, 462–467 (2019).
Penalver Bernabe, B., Cralle, L. & Gilbert, J. A. Systems biology of the human microbiome. Curr. Opin. Biotechnol. 51, 146–153 (2018).
Enright, E. F., Gahan, C. G., Joyce, S. A. & Griffin, B. T. The impact of the gut microbiota on drug metabolism and clinical outcome. Yale J. Biol. Med. 89, 375–382 (2016).
Kinross, J. M., Darzi, A. W. & Nicholson, J. K. Gut microbiome-host interactions in health and disease. Genome Med. 3, 14 (2011).
Rodriguez, J. M. et al. The composition of the gut microbiota throughout life, with an emphasis on early life. Micro. Ecol. Health Dis. 26, 26050 (2015).
Piazzon, M. C. et al. Under control: how a dietary additive can restore the gut microbiome and proteomic profile, and improve disease resilience in a marine teleostean fish fed vegetable diets. Microbiome 5, 164 (2017).
Shkoporov, A. N. et al. Reproducible protocols for metagenomic analysis of human faecal phageomes. Microbiome 6, 68 (2018).
Montassier, E. et al. CLOUD: a non-parametric detection test for microbiome outliers. Microbiome 6, 137 (2018).
Huang, L. et al. Analysis of microbiota in elderly patients with Acute Cerebral Infarction. PeerJ 7, e6928 (2019).
Jiang, H. et al. Impact of host intraspecies genetic variation, diet, and age on bacterial and fungal intestinal microbiota in tigers. Microbiologyopen 9, e1050 (2020).
Visconti, A. et al. Interplay between the human gut microbiome and host metabolism. Nat. Commun. 10, 4505 (2019).
Chua, L. L. et al. Reduced microbial diversity in adult survivors of childhood acute lymphoblastic leukemia and microbial associations with increased immune activation. Microbiome 5, 35 (2017).
Jackson, M. A. et al. Gut microbiota associations with common diseases and prescription medications in a population-based cohort. Nat. Commun. 9, 2655 (2018).
Heirali, A. A. et al. The effects of inhaled aztreonam on the cystic fibrosis lung microbiome. Microbiome 5, 51 (2017).
Javdan, B. et al. Personalized mapping of drug metabolism by the human gut microbiome. Cell 181, 1661–1679.e22 (2020).
Weersma, R. K., Zhernakova, A. & Fu, J. Interaction between drugs and the gut microbiome. Gut 69, 1510–1519 (2020).
Alexander, J. L. et al. Gut microbiota modulation of chemotherapy efficacy and toxicity. Nat. Rev. Gastroenterol. Hepatol. 14, 356–365 (2017).
Saad, R., Rizkallah, M. R. & Aziz, R. K. Gut Pharmacomicrobiomics: the tip of an iceberg of complex interactions between drugs and gut-associated microbes. Gut Pathog. 4, 16 (2012).
Scher, J. U., Nayak, R. R., Ubeda, C., Turnbaugh, P. J. & Abramson, S. B. Pharmacomicrobiomics in inflammatory arthritis: gut microbiome as modulator of therapeutic response. Nat. Rev. Rheumatol. 16, 282–292 (2020).
Ting, N. L., Lau, H. C. & Yu, J. Cancer pharmacomicrobiomics: targeting microbiota to optimise cancer therapy outcomes. Gut 71, 1412–1425 (2022).
Panebianco, C., Andriulli, A. & Pazienza, V. Pharmacomicrobiomics: exploiting the drug-microbiota interactions in anticancer therapies. Microbiome 6, 92 (2018).
Doestzada, M. et al. Pharmacomicrobiomics: a novel route towards personalized medicine? Protein Cell 9, 432–445 (2018).
Hassan, R. et al. Drug response in association with pharmacogenomics and pharmacomicrobiomics: towards a better personalized medicine. Brief. Bioinform 22, bbaa292 (2021).
Sharma, A., Buschmann, M. M. & Gilbert, J. A. Pharmacomicrobiomics: the holy grail to variability in drug response? Clin. Pharm. Ther. 106, 317–328 (2019).
Tsunoda, S. M., Gonzales, C., Jarmusch, A. K., Momper, J. D. & Ma, J. D. Contribution of the gut microbiome to drug disposition, pharmacokinetic and pharmacodynamic variability. Clin. Pharmacokinet. 60, 971–984 (2021).
Lee, H. L. et al. Targeted approaches for in situ gut microbiome manipulation. Genes (Basel) 9, 351 (2018).
Wong, W. F. & Santiago, M. Microbial approaches for targeting antibiotic-resistant bacteria. Micro. Biotechnol. 10, 1047–1053 (2017).
El Rouby, N., Lima, J. J. & Johnson, J. A. Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine. Expert Opin. Drug Metab. Toxicol. 14, 447–460 (2018).
Hauser, A. S. et al. Pharmacogenomics of GPCR drug targets. Cell 172, 41–54 e19 (2018).
Chaudhry, S. R. et al. Pharmacogenetic prediction of individual variability in drug response based on CYP2D6, CYP2C9 and CYP2C19 genetic polymorphisms. Curr. Drug Metab. 15, 711–718 (2014).
Muszkat, M. Interethnic differences in drug response: the contribution of genetic variability in beta adrenergic receptor and cytochrome P4502C9. Clin. Pharm. Ther. 82, 215–218 (2007).
Kamath, A. et al. Role of drug transporters in elucidating inter-individual variability in pediatric chemotherapy-related toxicities and response. Pharmaceuticals 15, 990 (2022).
Joharatnam-Hogan, N., Shiu, K. K. & Khan, K. Challenges in the treatment of gastric cancer in the older patient. Cancer Treat. Rev. 85, 101980 (2020).
Murgo, A. J. & Espinoza-Delgado, I. Development of novel anticancer agents in older patients: pharmacokinetic, pharmacodynamic, and other considerations. Cancer J. 11, 481–487 (2005).
Schwartz, J. B. The current state of knowledge on age, sex, and their interactions on clinical pharmacology. Clin. Pharm. Ther. 82, 87–96 (2007).
Deneer, V. H. & van Hemel, N. M. Is antiarrhythmic treatment in the elderly different? a review of the specific changes. Drugs Aging 28, 617–633 (2011).
Besir, F. H. et al. Enoxaparin-associated giant retroperitoneal hematoma in pulmonary embolism treatment. N. Am. J. Med. Sci. 3, 524–526 (2011).
Spirk, D. et al. Predictors of in-hospital mortality in elderly patients with acute venous thrombo-embolism: the SWIss Venous ThromboEmbolism Registry (SWIVTER). Eur. Heart J. 33, 921–926 (2012).
Saltalamacchia, G., Frascaroli, M., Bernardo, A. & Quaquarini, E. Renal and cardiovascular toxicities by new systemic treatments for prostate cancer. Cancers (Basel) 12, 1750 (2020).
Masnoon, N., Shakib, S., Kalisch-Ellett, L. & Caughey, G. E. What is polypharmacy? A systematic review of definitions. BMC Geriatr. 17, 230 (2017).
Scherholz, M. L., Rao, R. T. & Androulakis, I. P. Modeling inter-sex and inter-individual variability in response to chronopharmacological administration of synthetic glucocorticoids. Chronobiol. Int. 37, 281–296 (2020).
Conforti, F. et al. Sex-based differences in response to anti-PD-1 or PD-L1 treatment in patients with non-small-cell lung cancer expressing high PD-L1 levels. A systematic review and meta-analysis of randomized clinical trials. ESMO Open 6, 100251 (2021).
Federman, D. D. The biology of human sex differences. N. Engl. J. Med. 354, 1507–1514 (2006).
Soldin, O. P. & Mattison, D. R. Sex differences in pharmacokinetics and pharmacodynamics. Clin. Pharmacokinet. 48, 143–157 (2009).
Scandlyn, M. J., Stuart, E. C. & Rosengren, R. J. Sex-specific differences in CYP450 isoforms in humans. Expert Opin. Drug Metab. Toxicol. 4, 413–424 (2008).
Rodenburg, E. M., Stricker, B. H. & Visser, L. E. Sex-related differences in hospital admissions attributed to adverse drug reactions in the Netherlands. Br. J. Clin. Pharm. 71, 95–104 (2011).
Calcagno, A. et al. Tenofovir plasma concentrations according to companion drugs: a cross-sectional study of HIV-positive patients with normal renal function. Antimicrob. Agents Chemother. 57, 1840–1843 (2013).
Cerrato, E. et al. Cardiovascular disease in HIV patients: from bench to bedside and backwards. Open Heart 2, e000174 (2015).
Anderson, G. D. Sex and racial differences in pharmacological response: where is the evidence? Pharmacogenetics, pharmacokinetics, and pharmacodynamics. J. Women’s Health (Larchmt.) 14, 19–29 (2005).
Anderson, G. D. Gender differences in pharmacological response. Int. Rev. Neurobiol. 83, 1–10 (2008).
Siguret, V., Pautas, E. & Gouin-Thibault, I. Warfarin therapy: influence of pharmacogenetic and environmental factors on the anticoagulant response to warfarin. Vitam. Horm. 78, 247–264 (2008).
Hirsh, J. et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 119, 8S–21S (2001).
Cavallari, L. H. & Limdi, N. A. Warfarin pharmacogenomics. Curr. Opin. Mol. Ther. 11, 243–251 (2009).
Park, J. N., Lee, J. S., Noh, M. Y. & Sung, M. K. Association between usual vitamin K intake and anticoagulation in patients under warfarin therapy. Clin. Nutr. Res. 4, 235–241 (2015).
Guaraldi, G. et al. Efficacy and safety of atazanavir in patients with end-stage liver disease. Infection 37, 250–255 (2009).
Greenblatt, D. J., Shader, R. I. & Lofgren, S. Rational psycho-pharmacology for patients with medical diseases. Annu Rev. Med. 27, 407–420 (1976).
Lv, C., Lv, J., Liu, Y., Liu, Q. & Zou, D. Pediatric pharmaceutical care with anti-infective medication in a patient with acute hematogenous osteomyelitis caused by methicillin-resistant Staphylococcus aureus. Int J. Immunopathol. Pharm. 34, 2058738420925713 (2020).
Waldinger, R., Weinberg, G. & Gitman, M. Local anesthetic toxicity in the geriatric population. Drugs Aging 37, 1–9 (2020).
Rosmarin, D. M., Lebwohl, M., Elewski, B. E. & Gottlieb, A. B., National Psoriasis, F. Cyclosporine and psoriasis: 2008 National Psoriasis Foundation Consensus Conference. J. Am. Acad. Dermatol. 62, 838–853 (2010).
Lewis, J. H. & Stine, J. G. Review article: prescribing medications in patients with cirrhosis – a practical guide. Aliment Pharm. Ther. 37, 1132–1156 (2013).
Verbeeck, R. K. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur. J. Clin. Pharm. 64, 1147–1161 (2008).
Macpherson, A. J., Heikenwalder, M. & Ganal-Vonarburg, S. C. The liver at the nexus of host-microbial interactions. Cell Host Microbe 20, 561–571 (2016).
Mani, R. & Pollard, J. R. Antiepileptic drugs and other medications: what interactions may arise? Curr. Treat. Options Neurol. 11, 253–261 (2009).
Huang, L., Lizak, P., Dvorak, C. C., Aweeka, F. & Long-Boyle, J. Simultaneous determination of fludarabine and clofarabine in human plasma by LC-MS/MS. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 960, 194–199 (2014).
Relling, M. V. et al. Adverse effect of anticonvulsants on efficacy of chemotherapy for acute lymphoblastic leukaemia. Lancet 356, 285–290 (2000).
Rendic, S. Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab. Rev. 34, 83–448 (2002).
O’Malley, M., Healy, P., Daignault, S. & Ramnath, N. Cigarette smoking and gemcitabine-induced neutropenia in advanced solid tumors. Oncology 85, 216–222 (2013).
Hamilton, M. et al. Effects of smoking on the pharmacokinetics of erlotinib. Clin. Cancer Res. 12, 2166–2171 (2006).
Hughes, A. N. et al. Overcoming CYP1A1/1A2 mediated induction of metabolism by escalating erlotinib dose in current smokers. J. Clin. Oncol. 27, 1220–1226 (2009).
van der Bol, J. M. et al. Cigarette smoking and irinotecan treatment: pharmacokinetic interaction and effects on neutropenia. J. Clin. Oncol. 25, 2719–2726 (2007).
Kanai, M. et al. A history of smoking is inversely correlated with the incidence of gemcitabine-induced neutropenia. Ann. Oncol. 20, 1397–1401 (2009).
Dikeocha, I. J., Al-Kabsi, A. M., Miftahussurur, M. & Alshawsh, M. A. Pharmacomicrobiomics: Influence of gut microbiota on drug and xenobiotic metabolism. FASEB J. 36, e22350 (2022).
Enright, E. F., Griffin, B. T., Gahan, C. G. M. & Joyce, S. A. Microbiome-mediated bile acid modification: Role in intestinal drug absorption and metabolism. Pharm. Res. 133, 170–186 (2018).
Vich Vila, A. et al. Impact of commonly used drugs on the composition and metabolic function of the gut microbiota. Nat. Commun. 11, 362 (2020).
Garrod, A. E. The incidence of alkaptonuria: a study in chemical individuality. 1902 [classical article]. Yale J. Biol. Med. 75, 221–231 (2002).
Perlman, R. L. & Govindaraju, D. R. Archibald E. Garrod: the father of precision medicine. Genet Med. 18, 1088–1089 (2016).
Evans, W. E. & Relling, M. V. Moving towards individualized medicine with pharmacogenomics. Nature 429, 464–468 (2004).
Evans, W. E. & McLeod, H. L. Pharmacogenomics-drug disposition, drug targets, and side effects. N. Engl. J. Med. 348, 538–549 (2003).
Weinshilboum, R. Inheritance and drug response. N. Engl. J. Med. 348, 529–537 (2003).
Dawed, A. Y. et al. Pharmacogenomics of GLP-1 receptor agonists: a genome-wide analysis of observational data and large randomised controlled trials. Lancet Diabetes Endocrinol. 11, 33–41 (2023).
Beutler, E. Drug-induced hemolytic anemia. Pharm. Rev. 21, 73–103 (1969).
Beutler, E. The hemolytic effect of primaquine and related compounds: a review. Blood 14, 103–139 (1959).
Beutler, E., Dern, R. J. & Alving, A. S. The hemolytic effect of primaquine. III. A study of primaquine-sensitive erythrocytes. J. Lab Clin. Med. 44, 177–184 (1954).
Vogel, F. Moderne probleme der humangenetik. Ergebn. Inn. Med. Kinderheilk 12, 52–125 (1959).
Xu, H. et al. Multiplexed SNP genotyping using the Qbead system: a quantum dot-encoded microsphere-based assay. Nucleic Acids Res. 31, e43 (2003).
Gibbs, R. A. The Human Genome Project changed everything. Nat. Rev. Genet 21, 575–576 (2020).
Nebert, D. W., Zhang, G. & Vesell, E. S. From human genetics and genomics to pharmacogenetics and pharmacogenomics: past lessons, future directions. Drug Metab. Rev. 40, 187–224 (2008).
Ruiz, C., Zitnik, M. & Leskovec, J. Identification of disease treatment mechanisms through the multiscale interactome. Nat. Commun. 12, 1796 (2021).
Ming, X. & Laing, B. Bioconjugates for targeted delivery of therapeutic oligonucleotides. Adv. Drug Deliv. Rev. 87, 81–89 (2015).
Higgins, G. A., Williams, A. M., Ade, A. S., Alam, H. B. & Athey, B. D. Druggable transcriptional networks in the human neurogenic epigenome. Pharm. Rev. 71, 520–538 (2019).
Varga, J., Dobson, L., Remenyi, I. & Tusnady, G. E. TSTMP: target selection for structural genomics of human transmembrane proteins. Nucleic Acids Res. 45, D325–D330 (2017).
Somogyi, A. A. & Phillips, E. Genomic testing as a tool to optimise drug therapy. Aust. Prescr. 40, 101–104 (2017).
Tam, H. K. et al. Allosteric drug transport mechanism of multidrug transporter AcrB. Nat. Commun. 12, 3889 (2021).
van de Ven, R. et al. A role for multidrug resistance protein 4 (MRP4; ABCC4) in human dendritic cell migration. Blood 112, 2353–2359 (2008).
Oslin, D. W. et al. Effect of pharmacogenomic testing for drug-gene interactions on medication selection and remission of symptoms in major depressive disorder: the PRIME care randomized clinical trial. JAMA 328, 151–161 (2022).
Tardif, J. C. et al. Pharmacogenetics-guided dalcetrapib therapy after an acute coronary syndrome: the dal-GenE trial. Eur. Heart J. 43, 3947–3956 (2022).
Tsutsumi, K. et al. Structures of the wild-type MexAB-OprM tripartite pump reveal its complex formation and drug efflux mechanism. Nat. Commun. 10, 1520 (2019).
Nigam, S. K. What do drug transporters really do? Nat. Rev. Drug Discov. 14, 29–44 (2015).
Surendiran, A., Pradhan, S. C. & Adithan, C. Role of pharmacogenomics in drug discovery and development. Indian J. Pharm. 40, 137–143 (2008).
Clayton, T. A., Baker, D., Lindon, J. C., Everett, J. R. & Nicholson, J. K. Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism. Proc. Natl Acad. Sci. USA 106, 14728–14733 (2009).
Zhou, H. H., Koshakji, R. P., Silberstein, D. J., Wilkinson, G. R. & Wood, A. J. Racial differences in drug response. Altered sensitivity to and clearance of propranolol in men of Chinese descent as compared with American whites. N. Engl. J. Med. 320, 565–570 (1989).
Yasuda, S. U., Zhang, L. & Huang, S. M. The role of ethnicity in variability in response to drugs: focus on clinical pharmacology studies. Clin. Pharm. Ther. 84, 417–423 (2008).
Man, M. et al. Genetic variation in metabolizing enzyme and transporter genes: comprehensive assessment in 3 major East Asian subpopulations with comparison to Caucasians and Africans. J. Clin. Pharm. 50, 929–940 (2010).
Scharfe, C. P. I., Tremmel, R., Schwab, M., Kohlbacher, O. & Marks, D. S. Genetic variation in human drug-related genes. Genome Med. 9, 117 (2017).
Bernard, E. et al. Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. Nat. Med. 26, 1549–1556 (2020).
Taylor, C. A. et al. IL7 genetic variation and toxicity to immune checkpoint blockade in patients with melanoma. Nat. Med. 28, 2592–2600 (2022).
Funnell, T. et al. Single-cell genomic variation induced by mutational processes in cancer. Nature 612, 106–115 (2022).
Martinez-Ruiz, C. et al. Genomic-transcriptomic evolution in lung cancer and metastasis. Nature 616, 543–552 (2023).
Naranbhai, V. et al. HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study. Lancet Oncol. 23, 172–184 (2022).
Wang, C. W., Preclaro, I. A. C., Lin, W. H. & Chung, W. H. An updated review of genetic associations with severe adverse drug reactions: translation and implementation of pharmacogenomic testing in clinical practice. Front. Pharm. 13, 886377 (2022).
Khan, D. A., Knowles, S. R. & Shear, N. H. Sulfonamide hypersensitivity: fact and fiction. J. Allergy Clin. Immunol. Pract. 7, 2116–2123 (2019).
Chow, T. G. & Khan, D. A. Sulfonamide hypersensitivity. Clin. Rev. Allergy Immunol. 62, 400–412 (2022).
Neuman, M. G. et al. Immunopathogenesis of hypersensitivity syndrome reactions to sulfonamides. Transl. Res. 149, 243–253 (2007).
Relman, D. A. & Falkow, S. The meaning and impact of the human genome sequence for microbiology. Trends Microbiol. 9, 206–208 (2001).
Maringanti, V. S., Bucci, V. & Gerber, G. K. MDITRE: scalable and interpretable machine learning for predicting host status from temporal microbiome dynamics. mSystems 7, e0013222 (2022).
Pflughoeft, K. J. & Versalovic, J. Human microbiome in health and disease. Annu. Rev. Pathol. 7, 99–122 (2012).
Geurtsen, J. et al. Expression of the lipopolysaccharide-modifying enzymes PagP and PagL modulates the endotoxic activity of Bordetella pertussis. Infect. Immun. 74, 5574–5585 (2006).
ElRakaiby, M. et al. Pharmacomicrobiomics: the impact of human microbiome variations on systems pharmacology and personalized therapeutics. OMICS 18, 402–414 (2014).
Gutierrez Lopez, D. E., Lashinger, L. M., Weinstock, G. M. & Bray, M. S. Circadian rhythms and the gut microbiome synchronize the host’s metabolic response to diet. Cell Metab. 33, 873–887 (2021).
Zheng, P. et al. Gut microbiome remodeling induces depressive-like behaviors through a pathway mediated by the host’s metabolism. Mol. Psychiatry 21, 786–796 (2016).
Xue, M. Y., Sun, H. Z., Wu, X. H., Liu, J. X. & Guan, L. L. Multi-omics reveals that the rumen microbiome and its metabolome together with the host metabolome contribute to individualized dairy cow performance. Microbiome 8, 64 (2020).
Wilson, I. D. & Nicholson, J. K. Gut microbiome interactions with drug metabolism, efficacy, and toxicity. Transl. Res. 179, 204–222 (2017).
Koppel, N., Maini Rekdal, V. & Balskus, E. P. Chemical transformation of xenobiotics by the human gut microbiota. Science 356, eaag2770 (2017).
Khalsa, J., Duffy, L. C., Riscuta, G., Starke-Reed, P. & Hubbard, V. S. Omics for understanding the gut-liver-microbiome axis and precision medicine. Clin. Pharm. Drug Dev. 6, 176–185 (2017).
Zhao, L. et al. Targeting the human genome-microbiome axis for drug discovery: inspirations from global systems biology and traditional Chinese medicine. J. Proteome Res. 11, 3509–3519 (2012).
Yachida, S. et al. Metagenomic and metabolomic analyses reveal distinct stage-specific phenotypes of the gut microbiota in colorectal cancer. Nat. Med. 25, 968–976 (2019).
Almeida, A. et al. A new genomic blueprint of the human gut microbiota. Nature 568, 499–504 (2019).
Qin, Y. et al. Combined effects of host genetics and diet on human gut microbiota and incident disease in a single population cohort. Nat. Genet 54, 134–142 (2022).
Li, Q. et al. Main active components of Jiawei Gegen Qinlian decoction protects against ulcerative colitis under different dietary environments in a gut microbiota-dependent manner. Pharm. Res. 170, 105694 (2021).
Kaddurah-Daouk, R. & Weinshilboum, R. Pharmacometabolomics Research Network Metabolomic signatures for drug response phenotypes: pharmacometabolomics enables precision medicine. Clin. Pharm. Ther. 98, 71–75 (2015).
Chakladar, J. et al. The liver microbiome is implicated in cancer prognosis and modulated by alcohol and hepatitis B. Cancers (Basel) 12, 1642 (2020).
Grierson, J., Flies, E. J., Bissett, A., Ammitzboll, H. & Jones, P. Which soil microbiome? Bacteria, fungi, and protozoa communities show different relationships with urban green space type and use-intensity. Sci. Total Environ. 863, 160468 (2023).
Wu, X., Xia, Y., He, F., Zhu, C. & Ren, W. Intestinal mycobiota in health and diseases: from a disrupted equilibrium to clinical opportunities. Microbiome 9, 60 (2021).
Berg, G. et al. Microbiome definition re-visited: old concepts and new challenges. Microbiome 8, 103 (2020).
El-Sayed, A., Aleya, L. & Kamel, M. Microbiota’s role in health and diseases. Environ. Sci. Pollut. Res. Int. 28, 36967–36983 (2021).
Marchesi, J. R. & Ravel, J. The vocabulary of microbiome research: a proposal. Microbiome 3, 31 (2015).
Rajendhran, J. & Gunasekaran, P. Microbial phylogeny and diversity: small subunit ribosomal RNA sequence analysis and beyond. Microbiol. Res. 166, 99–110 (2011).
Kumar, P. S. Microbiomics: were we all wrong before? Periodontol 2000 85, 8–11 (2021).
Dominguez-Bello, M. G., Godoy-Vitorino, F., Knight, R. & Blaser, M. J. Role of the microbiome in human development. Gut 68, 1108–1114 (2019).
Turnbaugh, P. J. et al. The human microbiome project. Nature 449, 804–810 (2007).
Proctor, L. M. The National Institutes of Health Human Microbiome Project. Semin. Fetal Neonatal Med. 21, 368–372 (2016).
Integrative, H.M.P.R.N.C. The Integrative Human Microbiome Project: dynamic analysis of microbiome-host omics profiles during periods of human health and disease. Cell Host Microbe 16, 276–289 (2014).
Gilbert, J. A. et al. The Earth Microbiome Project: Meeting report of the “1 EMP meeting on sample selection and acquisition” at Argonne National Laboratory October 6 2010. Stand Genom. Sci. 3, 249–253 (2010).
Gilbert, J. A., Jansson, J. K. & Knight, R. The Earth Microbiome project: successes and aspirations. BMC Biol. 12, 69 (2014).
McCoubrey, L. E., Gaisford, S., Orlu, M. & Basit, A. W. Predicting drug-microbiome interactions with machine learning. Biotechnol. Adv. 54, 107797 (2022).
Pryor, R., Martinez-Martinez, D., Quintaneiro, L. & Cabreiro, F. The role of the microbiome in drug response. Annu. Rev. Pharm. Toxicol. 60, 417–435 (2020).
Kamath, S., Stringer, A. M., Prestidge, C. A. & Joyce, P. Targeting the gut microbiome to control drug pharmacomicrobiomics: the next frontier in oral drug delivery. Expert Opin. Drug Deliv. 7, 1–17 (2023).
Becker, H. E. F., Demers, K., Derijks, L. J. J., Jonkers, D. & Penders, J. Current evidence and clinical relevance of drug-microbiota interactions in inflammatory bowel disease. Front. Microbiol. 14, 1107976 (2023).
Rizkallah, M. R., Saad, R. & Aziz, R. K. The Human Microbiome Project, personalized medicine and the birth of pharmacomicrobiomics. Curr. Pharm. Pers. Med. 8, 182–193 (2010).
Clayton, T. A. et al. Pharmaco-metabonomic phenotyping and personalized drug treatment. Nature 440, 1073–1077 (2006).
Nicholson, J. K., Wilson, I. D. & Lindon, J. C. Pharmacometabonomics as an effector for personalized medicine. Pharmacogenomics 12, 103–111 (2011).
Nayak, R. R. & Turnbaugh, P. J. Mirror, mirror on the wall: which microbiomes will help heal them all? BMC Med. 14, 72 (2016).
Balasopoulou, A., Patrinos, G. P. & Katsila, T. Pharmacometabolomics informs viromics toward precision medicine. Front. Pharm. 7, 411 (2016).
Katsila, T., Balasopoulou, A., Tsagaraki, I. & Patrinos, G. P. Pharmacomicrobiomics informs clinical pharmacogenomics. Pharmacogenomics 20, 731–739 (2019).
Wilson, I. D. Drugs, bugs, and personalized medicine: pharmacometabonomics enters the ring. Proc. Natl Acad. Sci. USA 106, 14187–14188 (2009).
Fu, J. et al. Pharmacometabonomics: data processing and statistical analysis. Brief. Bioinform. 22, bbab138 (2021).
Everett, J. R. From metabonomics to pharmacometabonomics: the role of metabolic profiling in personalized medicine. Front. Pharm. 7, 297 (2016).
Sorbara, M. T. & Pamer, E. G. Microbiome-based therapeutics. Nat. Rev. Microbiol. 20, 365–380 (2022).
Wainwright, M. & Kristiansen, J. E. On the 75th anniversary of Prontosil. Dyes Pigments 88, 231–234 (2010).
Bentley, R. Different roads to discovery; Prontosil (hence sulfa drugs) and penicillin (hence beta-lactams). J. Ind. Microbiol. Biotechnol. 36, 775–786 (2009).
Paranjape, K. et al. Unravelling the importance of the eukaryotic and bacterial communities and their relationship with Legionella spp. ecology in cooling towers: a complex network. Microbiome 8, 157 (2020).
Lepage, P. et al. A metagenomic insight into our gut’s microbiome. Gut 62, 146–158 (2013).
Valles-Colomer, M. et al. Meta-omics in inflammatory bowel disease research: applications, challenges, and guidelines. J. Crohns Colitis 10, 735–746 (2016).
Sha, G. et al. Integrated meta-omics study on rapid tylosin removal mechanism and dynamics of antibiotic resistance genes during aerobic thermophilic fermentation of tylosin mycelial dregs. Bioresour. Technol. 351, 127010 (2022).
McDaniel, E. A. et al. Prospects for multi-omics in the microbial ecology of water engineering. Water Res. 205, 117608 (2021).
Kaddurah-Daouk, R. & Weinshilboum, R. M. Pharmacometabolomics Research Network Pharmacometabolomics: implications for clinical pharmacology and systems pharmacology. Clin. Pharm. Ther. 95, 154–167 (2014).
Kaddurah-Daouk, R., Kristal, B. S. & Weinshilboum, R. M. Metabolomics: a global biochemical approach to drug response and disease. Annu. Rev. Pharm. Toxicol. 48, 653–683 (2008).
Nicholson, J. K. & Wilson, I. D. Opinion: understanding ‘global’ systems biology: metabonomics and the continuum of metabolism. Nat. Rev. Drug Discov. 2, 668–676 (2003).
Beger, R. D., Schmidt, M. A. & Kaddurah-Daouk, R. Current concepts in pharmacometabolomics, biomarker discovery, and precision medicine. Metabolites 10, 129 (2020).
Everett, J. R., Loo, R. L. & Pullen, F. S. Pharmacometabonomics and personalized medicine. Ann. Clin. Biochem. 50, 523–545 (2013).
Everett, J. R. Pharmacometabonomics in humans: a new tool for personalized medicine. Pharmacogenomics 16, 737–754 (2015).
Rosato, A. et al. From correlation to causation: analysis of metabolomics data using systems biology approaches. Metabolomics 14, 37 (2018).
McWhinney, S. R. & McLeod, H. L. Using germline genotype in cancer pharmacogenetic studies. Pharmacogenomics 10, 489–493 (2009).
Derosa, L. et al. Microbiota-centered interventions: the next breakthrough in immuno-oncology? Cancer Discov. 11, 2396–2412 (2021).
He, Y., Liu, Q. W., Liao, H. X. & Xu, W. W. Microbiota in cancer chemoradiotherapy resistance. Clin. Transl. Med. 11, e250 (2021).
Emadi, A., Jones, R. J. & Brodsky, R. A. Cyclophosphamide and cancer: golden anniversary. Nat. Rev. Clin. Oncol. 6, 638–647 (2009).
Gershwin, M. E., Goetzl, E. J. & Steinberg, A. D. Cyclophosphamide: use in practice. Ann. Intern. Med. 80, 531–540 (1974).
Patel, J. M. Metabolism and pulmonary toxicity of cyclophosphamide. Pharm. Ther. 47, 137–146 (1990).
Barnes, H., Holland, A. E., Westall, G. P., Goh, N. S. & Glaspole, I. N. Cyclophosphamide for connective tissue disease-associated interstitial lung disease. Cochrane Database Syst. Rev. 1, CD010908 (2018).
Clemente, C. G. et al. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 77, 1303–1310 (1996).
Zhang, L. et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 348, 203–213 (2003).
Katz, S. C. et al. T cell infiltrate predicts long-term survival following resection of colorectal cancer liver metastases. Ann. Surg. Oncol. 16, 2524–2530 (2009).
Jamiyan, T. et al. Prognostic impact of a tumor-infiltrating lymphocyte subtype in triple negative cancer of the breast. Breast Cancer 27, 880–892 (2020).
Roy, S. & Trinchieri, G. Microbiota: a key orchestrator of cancer therapy. Nat. Rev. Cancer 17, 271–285 (2017).
Viaud, S. et al. Cyclophosphamide induces differentiation of Th17 cells in cancer patients. Cancer Res. 71, 661–665 (2011).
Nakahara, T. et al. Cyclophosphamide enhances immunity by modulating the balance of dendritic cell subsets in lymphoid organs. Blood 115, 4384–4392 (2010).
Ghiringhelli, F. et al. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur. J. Immunol. 34, 336–344 (2004).
Bracci, L. et al. Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration. Clin. Cancer Res. 13, 644–653 (2007).
Sistigu, A. et al. Immunomodulatory effects of cyclophosphamide and implementations for vaccine design. Semin. Immunopathol. 33, 369–383 (2011).
Hughes, E. et al. T-cell modulation by cyclophosphamide for tumour therapy. Immunology 154, 62–68 (2018).
Madondo, M. T., Quinn, M. & Plebanski, M. Low dose cyclophosphamide: mechanisms of T cell modulation. Cancer Treat. Rev. 42, 3–9 (2016).
Zhao, C. et al. Post-transplant cyclophosphamide alters immune signatures and leads to impaired T cell reconstitution in allogeneic hematopoietic stem cell transplant. J. Hematol. Oncol. 15, 64 (2022).
Toulmonde, M., Demolis, P. & Houede, N. Salvage chemotherapy for hormone-refractory prostate cancer: association of Adriamycin and ifosfamide. Exp. Ther. Med. 1, 1005–1011 (2010).
Viaud, S. et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science 342, 971–976 (2013).
Yang, J., Liu, K. X., Qu, J. M. & Wang, X. D. The changes induced by cyclophosphamide in intestinal barrier and microflora in mice. Eur. J. Pharm. 714, 120–124 (2013).
Xu, X. & Zhang, X. Effects of cyclophosphamide on immune system and gut microbiota in mice. Microbiol. Res. 171, 97–106 (2015).
Daillere, R. et al. Enterococcus hirae and Barnesiella intestinihominis facilitate cyclophosphamide-induced therapeutic immunomodulatory effects. Immunity 45, 931–943 (2016).
Mego, M. et al. Prevention of irinotecan induced diarrhea by probiotics: a randomized double blind, placebo controlled pilot study. Complement Ther. Med. 23, 356–362 (2015).
Bleiberg, H. CPT-11 in gastrointestinal cancer. Eur. J. Cancer 35, 371–379 (1999).
Dobi, A., Gasque, P., Guiraud, P. & Selambarom, J. Irinotecan (CPT-11) canonical anti-cancer drug can also modulate antiviral and pro-inflammatory responses of primary human synovial fibroblasts. Cells 10, 1431 (2021).
Bailly, C. Irinotecan: 25 years of cancer treatment. Pharm. Res. 148, 104398 (2019).
Zhao, J. et al. In situ activation of STING pathway with polymeric SN38 for cancer chemoimmunotherapy. Biomaterials 268, 120542 (2021).
Karas, S. et al. Optimal sampling strategies for irinotecan (CPT-11) and its active metabolite (SN-38) in cancer patients. AAPS J. 22, 59 (2020).
Stringer, A. M. et al. Faecal microflora and beta-glucuronidase expression are altered in an irinotecan-induced diarrhea model in rats. Cancer Biol. Ther. 7, 1919–1925 (2008).
Flieger, D. et al. Phase II clinical trial for prevention of delayed diarrhea with cholestyramine/levofloxacin in the second-line treatment with irinotecan biweekly in patients with metastatic colorectal carcinoma. Oncology 72, 10–16 (2007).
Kehrer, D. F. et al. Modulation of irinotecan-induced diarrhea by cotreatment with neomycin in cancer patients. Clin. Cancer Res. 7, 1136–1141 (2001).
Leibovici, L. et al. Antibiotic prophylaxis in neutropenic patients: new evidence, practical decisions. Cancer 107, 1743–1751 (2006).
Wallace, B. D. et al. Alleviating cancer drug toxicity by inhibiting a bacterial enzyme. Science 330, 831–835 (2010).
Kong, R. et al. Old drug new use-amoxapine and its metabolites as potent bacterial beta-glucuronidase inhibitors for alleviating cancer drug toxicity. Clin. Cancer Res. 20, 3521–3530 (2014).
Huang, P. T. et al. Enhancement of CPT-11 antitumor activity by adenovirus-mediated expression of beta-glucuronidase in tumors. Cancer Gene Ther. 18, 381–389 (2011).
Cheng, K. W. et al. Pharmacological inhibition of bacterial beta-glucuronidase prevents irinotecan-induced diarrhea without impairing its antitumor efficacy in vivo. Pharm. Res. 139, 41–49 (2019).
Chamseddine, A. N. et al. Intestinal bacterial beta-glucuronidase as a possible predictive biomarker of irinotecan-induced diarrhea severity. Pharm. Ther. 199, 1–15 (2019).
Gallotti, B. et al. Effects of dietary fibre intake in chemotherapy-induced mucositis in murine model. Br. J. Nutr. 126, 853–864 (2021).
Takasuna, K. et al. Involvement of beta-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats. Cancer Res. 56, 3752–3757 (1996).
Songjang, W. et al. Tumor-promoting activity and proteomic profiling of cisplatin/oxaliplatin-derived DAMPs in cholangiocarcinoma cells. Int J. Mol. Sci. 23, 10540 (2022).
Skripova, V., Vlasenkova, R., Zhou, Y., Astsaturov, I. & Kiyamova, R. Identification of new regulators of pancreatic cancer cell sensitivity to oxaliplatin and cisplatin. Molecules 27, 1289 (2022).
Zhang, C., Xu, C., Gao, X. & Yao, Q. Platinum-based drugs for cancer therapy and anti-tumor strategies. Theranostics 12, 2115–2132 (2022).
Yamada, Y. et al. Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naive patients with advanced gastric cancer. Ann. Oncol. 26, 141–148 (2015).
Vaisman, A., Masutani, C., Hanaoka, F. & Chaney, S. G. Efficient translesion replication past oxaliplatin and cisplatin GpG adducts by human DNA polymerase eta. Biochemistry 39, 4575–4580 (2000).
Cruet-Hennequart, S., Glynn, M. T., Murillo, L. S., Coyne, S. & Carty, M. P. Enhanced DNA-PK-mediated RPA2 hyperphosphorylation in DNA polymerase eta-deficient human cells treated with cisplatin and oxaliplatin. DNA Repair (Amst.) 7, 582–596 (2008).
Lokody, I. Tumour microenvironment: bacterial balance affects cancer treatment. Nat. Rev. Cancer 14, 10 (2014).
Iida, N. et al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science 342, 967–970 (2013).
Roberti, M. P. et al. Chemotherapy-induced ileal crypt apoptosis and the ileal microbiome shape immunosurveillance and prognosis of proximal colon cancer. Nat. Med. 26, 919–931 (2020).
Bachem, A. et al. Microbiota-derived short-chain fatty acids promote the memory potential of antigen-activated CD8(+) T cells. Immunity 51, 285–297 e5 (2019).
He, Y. et al. Gut microbial metabolites facilitate anticancer therapy efficacy by modulating cytotoxic CD8(+) T cell immunity. Cell Metab. 33, 988–1000 e7 (2021).
Qin, S. et al. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4. Mol. Cancer 18, 155 (2019).
Andrews, L. P., Yano, H. & Vignali, D. A. A. Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups. Nat. Immunol. 20, 1425–1434 (2019).
Burugu, S., Dancsok, A. R. & Nielsen, T. O. Emerging targets in cancer immunotherapy. Semin Cancer Biol. 52, 39–52 (2018).
Vetizou, M. et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science 350, 1079–1084 (2015).
Sivan, A. et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science 350, 1084–1089 (2015).
Chaput, N. et al. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. Ann. Oncol. 28, 1368–1379 (2017).
Gopalakrishnan, V. et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 359, 97–103 (2018).
Routy, B. et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science 359, 91–97 (2018).
Matson, V. et al. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science 359, 104–108 (2018).
Tanoue, T. et al. A defined commensal consortium elicits CD8 T cells and anti-cancer immunity. Nature 565, 600–605 (2019).
Helmink, B. A. et al. B cells and tertiary lymphoid structures promote immunotherapy response. Nature 577, 549–555 (2020).
Poore, G. D. et al. Microbiome analyses of blood and tissues suggest cancer diagnostic approach. Nature 579, 567–574 (2020).
Costea, P. I. et al. Towards standards for human fecal sample processing in metagenomic studies. Nat. Biotechnol. 35, 1069–1076 (2017).
Tam, V. et al. Benefits and limitations of genome-wide association studies. Nat. Rev. Genet 20, 467–484 (2019).
Baruch, E. N. et al. Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients. Science 371, 602–609 (2021).
Davar, D. et al. Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients. Science 371, 595–602 (2021).
Jamison, D. T. et al. Disease Control Priorities in Developing Countries. 2nd edition. Washington (DC): The International Bank for Reconstruction and Development/ The World Bank (2006).
Ruan, Y. et al. Cardiovascular disease (CVD) and associated risk factors among older adults in six low-and middle-income countries: results from SAGE Wave 1. BMC Public Health 18, 778 (2018).
Nitsa, A. et al. Vitamin D in cardiovascular disease. Vivo 32, 977–981 (2018).
Roth, G. A. et al. Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015. J. Am. Coll. Cardiol. 70, 1–25 (2017).
Zuo, H. L. et al. Interactions of antithrombotic herbal medicines with Western cardiovascular drugs. Pharm. Res. 159, 104963 (2020).
Curini, L. & Amedei, A. Cardiovascular diseases and pharmacomicrobiomics: a perspective on possible treatment relevance. Biomedicines 9, 1338 (2021).
Kyoung, J., Atluri, R. R. & Yang, T. Resistance to antihypertensive drugs: is gut microbiota the missing link? Hypertension 79, 2138–2147 (2022).
Chakaroun, R. M., Olsson, L. M. & Backhed, F. The potential of tailoring the gut microbiome to prevent and treat cardiometabolic disease. Nat. Rev. Cardiol. 20, 217–235 (2023).
Yang, Z. et al. Gut microbiota and hypertension: association, mechanisms and treatment. Clin. Exp. Hypertens. 45, 2195135 (2023).
Chen, H. Q. et al. Pharmacomicrobiomics: exploiting the drug-microbiota interactions in antihypertensive treatment. Front. Med. (Lausanne) 8, 742394 (2021).
Pirmohamed, M. Warfarin: almost 60 years old and still causing problems. Br. J. Clin. Pharm. 62, 509–511 (2006).
Kimmel, S. E. Warfarin pharmacogenomics: current best evidence. J. Thromb. Haemost. 13, S266–S271 (2015).
Wu, S. et al. Warfarin and vitamin K epoxide reductase: a molecular accounting for observed inhibition. Blood 132, 647–657 (2018).
Czogalla, K. J. et al. Warfarin and vitamin K compete for binding to Phe55 in human VKOR. Nat. Struct. Mol. Biol. 24, 77–85 (2017).
Chen, X. et al. A novel vitamin K derived anticoagulant tolerant to genetic variations of vitamin K epoxide reductase. J. Thromb. Haemost. 19, 689–700 (2021).
Rishavy, M. A. et al. Warfarin alters vitamin K metabolism: a surprising mechanism of VKORC1 uncoupling necessitates an additional reductase. Blood 131, 2826–2835 (2018).
Wise, E. S. et al. The influence of VKORC1 and CYP2C9 mutations on warfarin response after total hip and knee arthroplasty. J. Orthop. 12, S145–S151 (2015).
Jorgensen, A. L., FitzGerald, R. J., Oyee, J., Pirmohamed, M. & Williamson, P. R. Influence of CYP2C9 and VKORC1 on patient response to warfarin: a systematic review and meta-analysis. PLoS One 7, e44064 (2012).
Xue, L. et al. Theory-based pharmacokinetics and pharmacodynamics of S- and R-warfarin and effects on international normalized ratio: influence of body size, composition and genotype in cardiac surgery patients. Br. J. Clin. Pharm. 83, 823–835 (2017).
Wang, L. et al. The gut microbes, Enterococcus and Escherichia-Shigella, affect the responses of heart valve replacement patients to the anticoagulant warfarin. Pharm. Res. 159, 104979 (2020).
Ward, N. C., Watts, G. F. & Eckel, R. H. Statin toxicity. Circ. Res. 124, 328–350 (2019).
Lim, G. B. Statins outperform dietary supplements for LDL-C lowering. Nat. Rev. Cardiol. 20, 6 (2023).
Dehnavi, S. et al. Statins and autoimmunity: state-of-the-art. Pharm. Ther. 214, 107614 (2020).
Arnett, D. K. et al. ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 140, e596–e646 (2019).
Zhou, Q. & Liao, J. K. Statins and cardiovascular diseases: from cholesterol lowering to pleiotropy. Curr. Pharm. Des. 15, 467–478 (2009).
Oesterle, A., Laufs, U. & Liao, J. K. Pleiotropic effects of statins on the cardiovascular system. Circ. Res. 120, 229–243 (2017).
Kim, J. et al. Alterations in gut microbiota by statin therapy and possible intermediate effects on hyperglycemia and hyperlipidemia. Front. Microbiol. 10, 1947 (2019).
Caparros-Martin, J. A. et al. Statin therapy causes gut dysbiosis in mice through a PXR-dependent mechanism. Microbiome 5, 95 (2017).
Tuteja, S. & Ferguson, J. F. Gut microbiome and response to cardiovascular drugs. Circ. Genom. Precis Med. 12, 421–429 (2019).
Campbell, T. J. & MacDonald, P. S. Digoxin in heart failure and cardiac arrhythmias. Med. J. Aust. 179, 98–102 (2003).
Patocka, J., Nepovimova, E., Wu, W. & Kuca, K. Digoxin: pharmacology and toxicology-A review. Environ. Toxicol. Pharm. 79, 103400 (2020).
Haiser, H. J. et al. Predicting and manipulating cardiac drug inactivation by the human gut bacterium Eggerthella lenta. Science 341, 295–298 (2013).
Saha, J. R., Butler, V. P. Jr, Neu, H. C. & Lindenbaum, J. Digoxin-inactivating bacteria: identification in human gut flora. Science 220, 325–327 (1983).
Bo, J. et al. Eggerthella lenta bloodstream infections: two cases and review of the literature. Future Microbiol. 15, 981–985 (2020).
Kageyama, A., Benno, Y. & Nakase, T. Phylogenetic evidence for the transfer of Eubacterium lentum to the genus Eggerthella as Eggerthella lenta gen. nov., comb. nov. Int J. Syst. Bacteriol. 49, 1725–1732 (1999).
Haiser, H. J., Seim, K. L., Balskus, E. P. & Turnbaugh, P. J. Mechanistic insight into digoxin inactivation by Eggerthella lenta augments our understanding of its pharmacokinetics. Gut Microbes 5, 233–238 (2014).
David, L. A. et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature 505, 559–563 (2014).
Evered, M. D., Robinson, M. M. & Richardson, M. A. Captopril given intracerebroventricularly, subcutaneously or by gavage inhibits angiotensin-converting enzyme activity in the rat brain. Eur. J. Pharm. 68, 443–449 (1980).
Antunes, A. M., Guerrante, R. D., Avila, J. P., Lins Mendes, F. M. & Fierro, I. M. Case study of patents related to captopril, Squibb’s first blockbuster. Expert Opin. Ther. Pat. 26, 1449–1457 (2016).
Berecek, K. H., Reaves, P. & Raizada, M. Effects of early perturbation of the renin-angiotensin system on cardiovascular remodeling in spontaneously hypertensive rats. Vasc. Pharm. 42, 93–98 (2005).
Wu, J. N. & Berecek, K. H. Prevention of genetic hypertension by early treatment of spontaneously hypertensive rats with the angiotensin converting enzyme inhibitor captopril. Hypertension 22, 139–146 (1993).
Zhang, L., Edwards, D. G. & Berecek, K. H. Effects of early captopril treatment and its removal on plasma angiotensin converting enzyme (ACE) activity and arginine vasopressin in hypertensive rats (SHR) and normotensive rats (WKY). Clin. Exp. Hypertens. 18, 201–226 (1996).
Wu, H., Lam, T. Y. C., Shum, T. F., Tsai, T. Y. & Chiou, J. Hypotensive effect of captopril on deoxycorticosterone acetate-salt-induced hypertensive rat is associated with gut microbiota alteration. Hypertens. Res. 45, 270–282 (2022).
Yang, T. et al. Sustained captopril-induced reduction in blood pressure is associated with alterations in gut-brain axis in the spontaneously hypertensive rat. J. Am. Heart Assoc. 8, e010721 (2019).
Yang, T., Richards, E. M., Pepine, C. J. & Raizada, M. K. The gut microbiota and the brain-gut-kidney axis in hypertension and chronic kidney disease. Nat. Rev. Nephrol. 14, 442–456 (2018).
Santisteban, M. M., Kim, S., Pepine, C. J. & Raizada, M. K. Brain-gut-bone marrow axis: implications for hypertension and related therapeutics. Circ. Res. 118, 1327–1336 (2016).
Li, H. B., Yang, T., Richards, E. M., Pepine, C. J. & Raizada, M. K. Maternal treatment with captopril persistently alters gut-brain communication and attenuates hypertension of male offspring. Hypertension 75, 1315–1324 (2020).
Qi, Y., Aranda, J. M., Rodriguez, V., Raizada, M. K. & Pepine, C. J. Impact of antibiotics on arterial blood pressure in a patient with resistant hypertension—a case report. Int J. Cardiol. 201, 157–158 (2015).
Angiotensin-Converting Enzyme Inhibitors. in LiverTox: Clinical and Research Information on Drug-Induced Liver Injury (Bethesda, 2012).
Wang, B. L., Pan, D. Q., Zhou, K. L., Lou, Y. Y. & Shi, J. H. Multi-spectroscopic approaches and molecular simulation research of the intermolecular interaction between the angiotensin-converting enzyme inhibitor (ACE inhibitor) benazepril and bovine serum albumin (BSA). Spectrochim. Acta A Mol. Biomol. Spectrosc. 212, 15–24 (2019).
Hou, F. F. et al. Efficacy and safety of benazepril for advanced chronic renal insufficiency. N. Engl. J. Med. 354, 131–140 (2006).
Senthong, V. et al. Intestinal microbiota-generated metabolite trimethylamine-N-oxide and 5-year mortality risk in stable coronary artery disease: the contributory role of intestinal microbiota in a COURAGE-like patient cohort. J. Am. Heart Assoc. 5, e002816 (2016).
Li, X. S. et al. Gut microbiota-dependent trimethylamine N-oxide in acute coronary syndromes: a prognostic marker for incident cardiovascular events beyond traditional risk factors. Eur. Heart J. 38, 814–824 (2017).
Tang, W. H. et al. Increased trimethylamine N-oxide portends high mortality risk independent of glycemic control in patients with type 2 diabetes mellitus. Clin. Chem. 63, 297–306 (2017).
Konop, M. et al. Enalapril decreases rat plasma concentration of TMAO, a gut bacteria-derived cardiovascular marker. Biomarkers 23, 380–385 (2018).
Romano, K. A., Vivas, E. I., Amador-Noguez, D. & Rey, F. E. Intestinal microbiota composition modulates choline bioavailability from diet and accumulation of the proatherogenic metabolite trimethylamine-N-oxide. mBio 6, e02481 (2015).
Craciun, S. & Balskus, E. P. Microbial conversion of choline to trimethylamine requires a glycyl radical enzyme. Proc. Natl Acad. Sci. USA 109, 21307–21312 (2012).
Nowinski, A. & Ufnal, M. Trimethylamine N-oxide: a harmful, protective or diagnostic marker in lifestyle diseases? Nutrition 46, 7–12 (2018).
Jaworska, K. et al. Hypertension in rats is associated with an increased permeability of the colon to TMA, a gut bacteria metabolite. PLoS One 12, e0189310 (2017).
Qi, X., Yun, C., Pang, Y. & Qiao, J. The impact of the gut microbiota on the reproductive and metabolic endocrine system. Gut Microbes 13, 1–21 (2021).
Cornejo-Pareja, I., Munoz-Garach, A., Clemente-Postigo, M. & Tinahones, F. J. Importance of gut microbiota in obesity. Eur. J. Clin. Nutr. 72, 26–37 (2019).
Pascale, A. et al. Microbiota and metabolic diseases. Endocrine 61, 357–371 (2018).
Neuman, H., Debelius, J. W., Knight, R. & Koren, O. Microbial endocrinology: the interplay between the microbiota and the endocrine system. FEMS Microbiol. Rev. 39, 509–521 (2015).
Han, Y. et al. Effect of metformin on all-cause and cardiovascular mortality in patients with coronary artery diseases: a systematic review and an updated meta-analysis. Cardiovasc Diabetol. 18, 96 (2019).
LaMoia, T. E. & Shulman, G. I. Cellular and molecular mechanisms of metformin action. Endocr. Rev. 42, 77–96 (2021).
Giusti, L. et al. The protective action of metformin against pro-inflammatory cytokine-induced human islet cell damage and the mechanisms involved. Cells 11, 2465 (2022).
Sundelin, E., Jensen, J. B., Jakobsen, S., Gormsen, L. C. & Jessen, N. Metformin biodistribution: a key to mechanisms of action? J. Clin. Endocrinol. Metab. 105, dgaa332 (2020).
Minamii, T., Nogami, M. & Ogawa, W. Mechanisms of metformin action: in and out of the gut. J. Diabetes Investig. 9, 701–703 (2018).
Rena, G., Hardie, D. G. & Pearson, E. R. The mechanisms of action of metformin. Diabetologia 60, 1577–1585 (2017).
Foretz, M., Guigas, B. & Viollet, B. Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus. Nat. Rev. Endocrinol. 15, 569–589 (2019).
Wu, H. et al. Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug. Nat. Med. 23, 850–858 (2017).
Sun, L. et al. Gut microbiota and intestinal FXR mediate the clinical benefits of metformin. Nat. Med. 24, 1919–1929 (2018).
Bryrup, T. et al. Metformin-induced changes of the gut microbiota in healthy young men: results of a non-blinded, one-armed intervention study. Diabetologia 62, 1024–1035 (2019).
Pollak, M. The effects of metformin on gut microbiota and the immune system as research frontiers. Diabetologia 60, 1662–1667 (2017).
Duca, F. A. et al. Metformin activates a duodenal Ampk-dependent pathway to lower hepatic glucose production in rats. Nat. Med. 21, 506–511 (2015).
Luo, F. et al. Metformin in patients with and without diabetes: a paradigm shift in cardiovascular disease management. Cardiovasc. Diabetol. 18, 54 (2019).
Dalile, B., Van Oudenhove, L., Vervliet, B. & Verbeke, K. The role of short-chain fatty acids in microbiota-gut-brain communication. Nat. Rev. Gastroenterol. Hepatol. 16, 461–478 (2019).
Agrawal, N., Sharma, M., Singh, S. & Goyal, A. Recent advances of alpha-glucosidase inhibitors: a comprehensive review. Curr. Top. Med. Chem. 22, 2069–2086 (2022).
Dhameja, M. & Gupta, P. Synthetic heterocyclic candidates as promising alpha-glucosidase inhibitors: an overview. Eur. J. Med. Chem. 176, 343–377 (2019).
Zhang, X. et al. Effects of acarbose on the gut microbiota of prediabetic patients: a randomized, double-blind, controlled crossover trial. Diabetes Ther. 8, 293–307 (2017).
Brunkhorst, C., Andersen, C. & Schneider, E. Acarbose, a pseudooligosaccharide, is transported but not metabolized by the maltose-maltodextrin system of Escherichia coli. J. Bacteriol. 181, 2612–2619 (1999).
Yadav, H., Jain, S. & Sinha, P. R. Effect of Dahi containing Lactococcus lactis on the progression of diabetes induced by a high-fructose diet in rats. Biosci. Biotechnol. Biochem. 70, 1255–1258 (2006).
Yadav, H., Jain, S. & Sinha, P. R. Antidiabetic effect of probiotic dahi containing Lactobacillus acidophilus and Lactobacillus casei in high fructose fed rats. Nutrition 23, 62–68 (2007).
Kaushal, D. & Kansal, V. K. Dahi containing Lactobacillus acidophilus and Bifidobacterium bifidum improves phagocytic potential of macrophages in aged mice. J. Food Sci. Technol. 51, 1147–1153 (2014).
Su, B. et al. Acarbose treatment affects the serum levels of inflammatory cytokines and the gut content of bifidobacteria in Chinese patients with type 2 diabetes mellitus. J. Diabetes 7, 729–739 (2015).
Maruhama, Y. et al. Effects of a glucoside-hydrolase inhibitor (Bay g 5421) on serum lipids, lipoproteins and bile acids, fecal fat and bacterial flora, and intestinal gas production in hyperlipidemic patients. Tohoku J. Exp. Med. 132, 453–462 (1980).
Kishida, Y., Okubo, H., Ohno, H., Oki, K. & Yoneda, M. Effect of miglitol on the suppression of nonalcoholic steatohepatitis development and improvement of the gut environment in a rodent model. J. Gastroenterol. 52, 1180–1191 (2017).
Drucker, D. J. & Nauck, M. A. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368, 1696–1705 (2006).
Meier, J. J. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat. Rev. Endocrinol. 8, 728–742 (2012).
Drucker, D. J. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 27, 740–756 (2018).
Baggio, L. L. & Drucker, D. J. Glucagon-like peptide-1 receptors in the brain: controlling food intake and body weight. J. Clin. Invest. 124, 4223–4226 (2014).
Tolhurst, G. et al. Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2. Diabetes 61, 364–371 (2012).
Kimura, I. et al. The gut microbiota suppresses insulin-mediated fat accumulation via the short-chain fatty acid receptor GPR43. Nat. Commun. 4, 1829 (2013).
Vettorazzi, J. F. et al. The bile acid TUDCA increases glucose-induced insulin secretion via the cAMP/PKA pathway in pancreatic beta cells. Metabolism 65, 54–63 (2016).
Aoki, R. et al. A proliferative probiotic Bifidobacterium strain in the gut ameliorates progression of metabolic disorders via microbiota modulation and acetate elevation. Sci. Rep. 7, 43522 (2017).
Wang, L., Li, P., Tang, Z., Yan, X. & Feng, B. Structural modulation of the gut microbiota and the relationship with body weight: compared evaluation of liraglutide and saxagliptin treatment. Sci. Rep. 6, 33251 (2016).
Zhang, Q. et al. Featured article: structure moderation of gut microbiota in liraglutide-treated diabetic male rats. Exp. Biol. Med. (Maywood) 243, 34–44 (2018).
Zhao, L. et al. A glucagon-like peptide-1 receptor agonist lowers weight by modulating the structure of gut microbiota. Front. Endocrinol. (Lausanne) 9, 233 (2018).
Charpentier, J. et al. Liraglutide targets the gut microbiota and the intestinal immune system to regulate insulin secretion. Acta Diabetol. 58, 881–897 (2021).
Shang, J. et al. Liraglutide-induced structural modulation of the gut microbiota in patients with type 2 diabetes mellitus. PeerJ 9, e11128 (2021).
Yuan, X. et al. Identification of therapeutic effect of glucagon-like peptide 1 in the treatment of STZ-induced diabetes mellitus in rats by restoring the balance of intestinal flora. J. Cell Biochem. 119, 10067–10074 (2018).
Handelsman, Y. et al. American association of clinical endocrinologists and american college of endocrinology—clinical practice guidelines for developing a diabetes mellitus comprehensive care plan – 2015. Endocr. Pract. 21, 1–87 (2015).
Olivares, M. et al. The potential role of the dipeptidyl peptidase-4-like activity from the gut microbiota on the host health. Front. Microbiol. 9, 1900 (2018).
Liao, X. et al. Alteration of gut microbiota induced by DPP-4i treatment improves glucose homeostasis. EBioMedicine 44, 665–674 (2019).
Yan, X., Feng, B., Li, P., Tang, Z. & Wang, L. Microflora disturbance during progression of glucose intolerance and effect of sitagliptin: an animal study. J. Diabetes Res. 2016, 2093171 (2016).
Zhang, Q. et al. Vildagliptin increases butyrate-producing bacteria in the gut of diabetic rats. PLoS One 12, e0184735 (2017).
Zhao, X. et al. Host-microbiota interaction-mediated resistance to inflammatory bowel disease in pigs. Microbiome 10, 115 (2022).
Alshehri, D. et al. Dysbiosis of gut microbiota in inflammatory bowel disease: current therapies and potential for microbiota-modulating therapeutic approaches. Bosn. J. Basic Med. Sci. 21, 270–283 (2021).
Nilsson, A. et al. Olsalazine versus sulphasalazine for relapse prevention in ulcerative colitis: a multicenter study. Am. J. Gastroenterol. 90, 381–387 (1995).
Kim, D. H. Gut microbiota-mediated drug-antibiotic interactions. Drug Metab. Dispos. 43, 1581–1589 (2015).
Azad Khan, A. K., Guthrie, G., Johnston, H. H., Truelove, S. C. & Williamson, D. H. Tissue and bacterial splitting of sulphasalazine. Clin. Sci. (Lond.) 64, 349–354 (1983).
Lee, H. J., Zhang, H., Orlovich, D. A. & Fawcett, J. P. The influence of probiotic treatment on sulfasalazine metabolism in rat. Xenobiotica 42, 791–797 (2012).
Crouwel, F., Buiter, H. J. C. & de Boer, N. K. Gut microbiota-driven drug metabolism in inflammatory bowel disease. J. Crohns Colitis 15, 307–315 (2020).
Savarino, V. et al. The appropriate use of proton-pump inhibitors. Minerva Med 109, 386–399 (2018).
Graham, D. Y. & Tansel, A. Interchangeable use of proton pump inhibitors based on relative potency. Clin. Gastroenterol. Hepatol. 16, 800–808.e7 (2018).
Pinto-Sanchez, M. I., Yuan, Y., Bercik, P. & Moayyedi, P. Proton pump inhibitors for functional dyspepsia. Cochrane Database Syst. Rev. 3, CD011194 (2017).
Forgacs, I. & Loganayagam, A. Overprescribing proton pump inhibitors. BMJ 336, 2–3 (2008).
Akram, F., Huang, Y., Lim, V., Huggan, P. J. & Merchant, R. A. Proton pump inhibitors: are we still prescribing them without valid indications? Australas. Med. J. 7, 465–470 (2014).
Eid, S. M. et al. Patterns and predictors of proton pump inhibitor overuse among academic and non-academic hospitalists. Intern Med. 49, 2561–2568 (2010).
Bonder, M. J. et al. The influence of a short-term gluten-free diet on the human gut microbiome. Genome Med. 8, 45 (2016).
Jackson, M. A. et al. Proton pump inhibitors alter the composition of the gut microbiota. Gut 65, 749–756 (2016).
Imhann, F. et al. Proton pump inhibitors affect the gut microbiome. Gut 65, 740–748 (2016).
Freedberg, D. E. et al. Proton pump inhibitors alter specific taxa in the human gastrointestinal microbiome: a crossover trial. Gastroenterology 149, 883–885.e9 (2015).
Maier, L. et al. Extensive impact of non-antibiotic drugs on human gut bacteria. Nature 555, 623–628 (2018).
Buffie, C. G. et al. Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile. Nature 517, 205–208 (2015).
Buffie, C. G. & Pamer, E. G. Microbiota-mediated colonization resistance against intestinal pathogens. Nat. Rev. Immunol. 13, 790–801 (2013).
Leonard, J., Marshall, J. K. & Moayyedi, P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am. J. Gastroenterol. 102, 2047–2056 (2007).
Baur, D. et al. Effect of antibiotic stewardship on the incidence of infection and colonisation with antibiotic-resistant bacteria and Clostridium difficile infection: a systematic review and meta-analysis. Lancet Infect. Dis. 17, 990–1001 (2017).
Bajaj, J. S. et al. Proton pump inhibitor initiation and withdrawal affects gut microbiota and readmission risk in cirrhosis. Am. J. Gastroenterol. 113, 1177–1186 (2018).
Stark, C. M., Susi, A., Emerick, J. & Nylund, C. M. Antibiotic and acid-suppression medications during early childhood are associated with obesity. Gut 68, 62–69 (2019).
Harirforoosh, S., Asghar, W. & Jamali, F. Adverse effects of nonsteroidal antiinflammatory drugs: an update of gastrointestinal, cardiovascular and renal complications. J. Pharm. Pharm. Sci. 16, 821–847 (2013).
Sostres, C., Gargallo, C. J. & Lanas, A. Nonsteroidal anti-inflammatory drugs and upper and lower gastrointestinal mucosal damage. Arthritis Res. Ther. 15, S3 (2013).
Higuchi, K. et al. Present status and strategy of NSAIDs-induced small bowel injury. J. Gastroenterol. 44, 879–888 (2009).
Petruzzelli, M. et al. Intestinal mucosal damage caused by non-steroidal anti-inflammatory drugs: role of bile salts. Clin. Biochem. 40, 503–510 (2007).
Boelsterli, U. A., Redinbo, M. R. & Saitta, K. S. Multiple NSAID-induced hits injure the small intestine: underlying mechanisms and novel strategies. Toxicol. Sci. 131, 654–667 (2013).
Yauw, S. T. K. et al. Microbial glucuronidase inhibition reduces severity of diclofenac-induced anastomotic leak in rats. Surg. Infect. (Larchmt.) 19, 417–423 (2018).
Dashnyam, P. et al. beta-Glucuronidases of opportunistic bacteria are the major contributors to xenobiotic-induced toxicity in the gut. Sci. Rep. 8, 16372 (2018).
Ervin, S. M. et al. Targeting regorafenib-induced toxicity through inhibition of gut microbial beta-glucuronidases. ACS Chem. Biol. 14, 2737–2744 (2019).
Yang, B., Liu, H., Yang, J., Gupta, V. K. & Jiang, Y. New insights on bioactivities and biosynthesis of flavonoid glycosides. Trends Food Sci. Technol. 79, 116–124 (2018).
Falony, G. et al. Population-level analysis of gut microbiome variation. Science 352, 560–564 (2016).
Dinan, T. G. & Cryan, J. F. The microbiome-gut-brain axis in health and disease. Gastroenterol. Clin. North Am. 46, 77–89 (2017).
LeWitt, P. A. Levodopa therapy for Parkinson’s disease: pharmacokinetics and pharmacodynamics. Mov. Disord. 30, 64–72 (2015).
Marsot, A., Guilhaumou, R., Azulay, J. P. & Blin, O. Levodopa in Parkinson’s disease: a review of population pharmacokinetics/pharmacodynamics analysis. J. Pharm. Pharm. Sci. 20, 226–238 (2017).
van Kessel, S. P. et al. Gut bacterial tyrosine decarboxylases restrict levels of levodopa in the treatment of Parkinson’s disease. Nat. Commun. 10, 310 (2019).
Maini Rekdal, V., Bess, E. N., Bisanz, J. E., Turnbaugh, P. J. & Balskus, E. P. Discovery and inhibition of an interspecies gut bacterial pathway for Levodopa metabolism. Science 364, eaau6323 (2019).
Musil, V., Blankova, A. & Baca, V. A plea for an extension of the anatomical nomenclature: the locomotor system. Bosn. J. Basic Med. Sci. 18, 117–125 (2018).
Peretti, S. et al. The Yin-Yang pharmacomicrobiomics on treatment response in inflammatory arthritides: a narrative review. Genes (Basel) 14, 89 (2022).
Zhao, S. et al. Drug repurposing by siderophore conjugation: synthesis and biological evaluation of siderophore-methotrexate conjugates as antibiotics. Angew. Chem. Int. Ed. Engl. 61, e202204139 (2022).
Romao, V. C., Lima, A., Bernardes, M., Canhao, H. & Fonseca, J. E. Three decades of low-dose methotrexate in rheumatoid arthritis: can we predict toxicity? Immunol. Res. 60, 289–310 (2014).
Ramos-Romero, S. et al. Mechanistically different effects of fat and sugar on insulin resistance, hypertension, and gut microbiota in rats. Am. J. Physiol. Endocrinol. Metab. 314, E552–E563 (2018).
Dunn, C. J. & Peters, D. H. Metformin. A review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus. Drugs 49, 721–749 (1995).
Zhou, B. et al. Induction and amelioration of methotrexate-induced gastrointestinal toxicity are related to immune response and gut microbiota. EBioMedicine 33, 122–133 (2018).
Sayers, E., MacGregor, A. & Carding, S. R. Drug-microbiota interactions and treatment response: relevance to rheumatoid arthritis. AIMS Microbiol. 4, 642–654 (2018).
Zhang, X. et al. The oral and gut microbiomes are perturbed in rheumatoid arthritis and partly normalized after treatment. Nat. Med. 21, 895–905 (2015).
Goodman, S. M., Cronstein, B. N. & Bykerk, V. P. Outcomes related to methotrexate dose and route of administration in patients with rheumatoid arthritis: a systematic literature review. Clin. Exp. Rheumatol. 33, 272–278 (2015).
Halilova, K. I. et al. Markers of treatment response to methotrexate in rheumatoid arthritis: where do we stand? Int. J. Rheumatol. 2012, 978396 (2012).
Angelis-Stoforidis, P., Vajda, F. J. & Christophidis, N. Methotrexate polyglutamate levels in circulating erythrocytes and polymorphs correlate with clinical efficacy in rheumatoid arthritis. Clin. Exp. Rheumatol. 17, 313–320 (1999).
Dervieux, T. et al. Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis. Arthritis Rheum. 50, 2766–2774 (2004).
Clemens, J. Q. Infection and inflammation of the genitourinary tract. J. Urol. 208, 455 (2022).
Choi, E., Buie, J., Camacho, J., Sharma, P. & de Riese, W. T. W. Evolution of androgen deprivation therapy (ADT) and its new emerging modalities in prostate cancer: an update for practicing urologists, clinicians and medical providers. Res. Rep. Urol. 14, 87–108 (2022).
Terrisse, S. et al. Immune system and intestinal microbiota determine efficacy of androgen deprivation therapy against prostate cancer. J. Immunother. Cancer 10, e004191 (2022).
Daisley, B. A. et al. Abiraterone acetate preferentially enriches for the gut commensal Akkermansia muciniphila in castrate-resistant prostate cancer patients. Nat. Commun. 11, 4822 (2020).
Sfanos, K. S., Yegnasubramanian, S., Nelson, W. G. & De Marzo, A. M. The inflammatory microenvironment and microbiome in prostate cancer development. Nat. Rev. Urol. 15, 11–24 (2018).
McCulloch, J. A. & Trinchieri, G. Gut bacteria enable prostate cancer growth. Science 374, 154–155 (2021).
Dickson, R. P., Erb-Downward, J. R., Martinez, F. J. & Huffnagle, G. B. The microbiome and the respiratory tract. Annu Rev. Physiol. 78, 481–504 (2016).
Unger, S. A. & Bogaert, D. The respiratory microbiome and respiratory infections. J. Infect. 74, S84–S88 (2017).
Man, W. H., de Steenhuijsen Piters, W. A. & Bogaert, D. The microbiota of the respiratory tract: gatekeeper to respiratory health. Nat. Rev. Microbiol. 15, 259–270 (2017).
Mi, J. et al. The research progress in immunotherapy of tuberculosis. Front. Cell Infect. Microbiol. 11, 763591 (2021).
Bermingham, W. H. et al. Practical management of suspected hypersensitivity reactions to anti-tuberculosis drugs. Clin. Exp. Allergy 52, 375–386 (2022).
Namasivayam, S. et al. Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy. Microbiome 5, 71 (2017).
Naidoo, C. C. et al. The microbiome and tuberculosis: state of the art, potential applications, and defining the clinical research agenda. Lancet Respir. Med. 7, 892–906 (2019).
Wipperman, M. F. et al. Antibiotic treatment for Tuberculosis induces a profound dysbiosis of the microbiome that persists long after therapy is completed. Sci. Rep. 7, 10767 (2017).
Shen, Y. et al. Outer membrane vesicles of a human commensal mediate immune regulation and disease protection. Cell Host Microbe 12, 509–520 (2012).
Larsen, J. M. The immune response to Prevotella bacteria in chronic inflammatory disease. Immunology 151, 363–374 (2017).
Wells, J. M. Immunomodulatory mechanisms of lactobacilli. Micro. Cell Fact. 10, S17 (2011).
Scriba, T. J. et al. Differential recognition of mycobacterium tuberculosis-specific epitopes as a function of tuberculosis disease history. Am. J. Respir. Crit. Care Med. 196, 772–781 (2017).
Hawn, T. R., Matheson, A. I., Maley, S. N. & Vandal, O. Host-directed therapeutics for tuberculosis: can we harness the host? Microbiol. Mol. Biol. Rev. 77, 608–627 (2013).
Caballero-Flores, G., Pickard, J. M. & Nunez, G. Microbiota-mediated colonization resistance: mechanisms and regulation. Nat. Rev. Microbiol. 21, 347–360 (2023).
Gong, X. et al. The interactions between gut microbiota and bioactive ingredients of traditional Chinese medicines: a review. Pharm. Res. 157, 104824 (2020).
Hayase, E. & Jenq, R. R. Role of the intestinal microbiome and microbial-derived metabolites in immune checkpoint blockade immunotherapy of cancer. Genome Med. 13, 107 (2021).
Peng, Y. et al. Role of gut microbiota in travel-related acquisition of extended spectrum beta-lactamase-producing Enterobacteriaceae. J. Travel Med. 28, taab022 (2021).
He, Z. et al. Gut microbiota-derived ursodeoxycholic acid from neonatal dairy calves improves intestinal homeostasis and colitis to attenuate extended-spectrum beta-lactamase-producing enteroaggregative Escherichia coli infection. Microbiome 10, 79 (2022).
Smet, A. et al. Broad-spectrum beta-lactamases among Enterobacteriaceae of animal origin: molecular aspects, mobility and impact on public health. FEMS Microbiol. Rev. 34, 295–316 (2010).
Piewngam, P. et al. Composition of the intestinal microbiota in extended-spectrum beta-lactamase-producing Enterobacteriaceae carriers and non-carriers in Thailand. Int J. Antimicrob. Agents 53, 435–441 (2019).
McCulloch, J. A. et al. Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1. Nat. Med. 28, 545–556 (2022).
Munier, A. L. et al. Comparative dynamics of the emergence of fluoroquinolone resistance in staphylococci from the nasal microbiota of patients treated with fluoroquinolones according to their environment. Int J. Antimicrob. Agents 46, 653–659 (2015).
de Lastours, V. & Fantin, B. Impact of fluoroquinolones on human microbiota. Focus on the emergence of antibiotic resistance. Future Microbiol. 10, 1241–1255 (2015).
Klunemann, M. et al. Bioaccumulation of therapeutic drugs by human gut bacteria. Nature 597, 533–538 (2021).
Abt, M. C., McKenney, P. T. & Pamer, E. G. Clostridium difficile colitis: pathogenesis and host defence. Nat. Rev. Microbiol. 14, 609–620 (2016).
O’Grady, K., Knight, D. R. & Riley, T. V. Antimicrobial resistance in Clostridioides difficile. Eur. J. Clin. Microbiol. Infect. Dis. 40, 2459–2478 (2021).
Gil, F. & Paredes-Sabja, D. Acyldepsipeptide antibiotics as a potential therapeutic agent against Clostridium difficile recurrent infections. Future Microbiol. 11, 1179–1189 (2016).
Liu, X., Chen, Y., Zhang, S. & Dong, L. Gut microbiota-mediated immunomodulation in tumor. J. Exp. Clin. Cancer Res. 40, 221 (2021).
Simpson, R. C. et al. Diet-driven microbial ecology underpins associations between cancer immunotherapy outcomes and the gut microbiome. Nat. Med. 28, 2344–2352 (2022).
Cheng, W. Y., Wu, C. Y. & Yu, J. The role of gut microbiota in cancer treatment: friend or foe? Gut 69, 1867–1876 (2020).
Li, X., Zhang, S., Guo, G., Han, J. & Yu, J. Gut microbiome in modulating immune checkpoint inhibitors. EBioMedicine 82, 104163 (2022).
Lu, Y. et al. Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies. J. Hematol. Oncol. 15, 47 (2022).
Paone, P. & Cani, P. D. Mucus barrier, mucins and gut microbiota: the expected slimy partners? Gut 69, 2232–2243 (2020).
Takiishi, T., Fenero, C. I. M. & Camara, N. O. S. Intestinal barrier and gut microbiota: shaping our immune responses throughout life. Tissue Barriers 5, e1373208 (2017).
Ianiro, G., Tilg, H. & Gasbarrini, A. Antibiotics as deep modulators of gut microbiota: between good and evil. Gut 65, 1906–1915 (2016).
Becattini, S., Taur, Y. & Pamer, E. G. Antibiotic-induced changes in the intestinal microbiota and disease. Trends Mol. Med. 22, 458–478 (2016).
Akbarali, H. I. & Dewey, W. L. Gastrointestinal motility, dysbiosis and opioid-induced tolerance: is there a link? Nat. Rev. Gastroenterol. Hepatol. 16, 323–324 (2019).
Kurz, A. & Sessler, D. I. Opioid-induced bowel dysfunction: pathophysiology and potential new therapies. Drugs 63, 649–671 (2003).
Mora, A. L. et al. Moderate to high use of opioid analgesics are associated with an increased risk of Clostridium difficile infection. Am. J. Med. Sci. 343, 277–280 (2012).
Zhuang, Y. P. et al. Gut microbiota interactions with antitumor immunity in colorectal cancer: from understanding to application. Biomed. Pharmacother. 165, 115040 (2023).
Pezo, R. C., Wong, M. & Martin, A. Impact of the gut microbiota on immune checkpoint inhibitor-associated toxicities. Ther. Adv. Gastroenterol. 12, 1756284819870911 (2019).
Bai, Z. et al. Aspirin ameliorates atherosclerotic immuno-inflammation through regulating the Treg/Th17 axis and CD39-CD73 adenosine signaling via remodeling the gut microbiota in ApoE(-/-) mice. Int. Immunopharmacol. 120, 110296 (2023).
Kolodziejczyk, A. A., Zheng, D. & Elinav, E. Diet-microbiota interactions and personalized nutrition. Nat. Rev. Microbiol. 17, 742–753 (2019).
Zmora, N., Suez, J. & Elinav, E. You are what you eat: diet, health and the gut microbiota. Nat. Rev. Gastroenterol. Hepatol. 16, 35–56 (2019).
Sanders, M. E., Merenstein, D. J., Reid, G., Gibson, G. R. & Rastall, R. A. Probiotics and prebiotics in intestinal health and disease: from biology to the clinic. Nat. Rev. Gastroenterol. Hepatol. 16, 605–616 (2019).
Lim, H. et al. Artificial intelligence approaches to human-microbiome protein-protein interactions. Curr. Opin. Struct. Biol. 73, 102328 (2022).
Cammarota, G. et al. Gut microbiome, big data and machine learning to promote precision medicine for cancer. Nat. Rev. Gastroenterol. Hepatol. 17, 635–648 (2020).
Vitetta, L., Coulson, S., Linnane, A. W. & Butt, H. The gastrointestinal microbiome and musculoskeletal diseases: a beneficial role for probiotics and prebiotics. Pathogens 2, 606–626 (2013).
Bermudez-Brito, M., Plaza-Diaz, J., Munoz-Quezada, S., Gomez-Llorente, C. & Gil, A. Probiotic mechanisms of action. Ann. Nutr. Metab. 61, 160–174 (2012).
Gupta, S., Allen-Vercoe, E. & Petrof, E. O. Fecal microbiota transplantation: in perspective. Ther. Adv. Gastroenterol. 9, 229–239 (2016).
Ser, H. L., Letchumanan, V., Goh, B. H., Wong, S. H. & Lee, L. H. The use of fecal microbiome transplant in treating human diseases: too early for poop? Front. Microbiol. 12, 519836 (2021).
Khoruts, A. Fecal microbiota transplantation-early steps on a long journey ahead. Gut Microbes 8, 199–204 (2017).
van Nood, E., Speelman, P., Nieuwdorp, M. & Keller, J. Fecal microbiota transplantation: facts and controversies. Curr. Opin. Gastroenterol. 30, 34–39 (2014).
Borody, T. J. & Campbell, J. Fecal microbiota transplantation: techniques, applications, and issues. Gastroenterol. Clin. North Am. 41, 781–803 (2012).
Li, M. et al. Pro- and anti-inflammatory effects of short chain fatty acids on immune and endothelial cells. Eur. J. Pharm. 831, 52–59 (2018).
Lin, D. M., Koskella, B. & Lin, H. C. Phage therapy: an alternative to antibiotics in the age of multi-drug resistance. World J. Gastrointest. Pharm. Ther. 8, 162–173 (2017).
Bourdin, G. et al. Coverage of diarrhoea-associated Escherichia coli isolates from different origins with two types of phage cocktails. Micro. Biotechnol. 7, 165–176 (2014).
Ackermann, H. W. The first phage electron micrographs. Bacteriophage 1, 225–227 (2011).
Rakhuba, D. V., Kolomiets, E. I., Dey, E. S. & Novik, G. I. Bacteriophage receptors, mechanisms of phage adsorption and penetration into host cell. Pol. J. Microbiol. 59, 145–155 (2010).
Motlagh, A. M., Bhattacharjee, A. S. & Goel, R. Biofilm control with natural and genetically-modified phages. World J. Microbiol Biotechnol. 32, 67 (2016).
Ramachandran, G. & Bikard, D. Editing the microbiome the CRISPR way. Philos. Trans. R. Soc. Lond. B Biol. Sci. 374, 20180103 (2019).
Reyes, A., Wu, M., McNulty, N. P., Rohwer, F. L. & Gordon, J. I. Gnotobiotic mouse model of phage-bacterial host dynamics in the human gut. Proc. Natl Acad. Sci. USA 110, 20236–20241 (2013).
Lusiak-Szelachowska, M., Weber-Dabrowska, B., Jonczyk-Matysiak, E., Wojciechowska, R. & Gorski, A. Bacteriophages in the gastrointestinal tract and their implications. Gut Pathog. 9, 44 (2017).
Divya Ganeshan, S. & Hosseinidoust, Z. Phage therapy with a focus on the human microbiota. Antibiotics (Basel) 8, 131 (2019).
Ren, Z. et al. Gut microbiome analysis as a tool towards targeted non-invasive biomarkers for early hepatocellular carcinoma. Gut 68, 1014–1023 (2019).
Scott, A. J. et al. International Cancer Microbiome Consortium consensus statement on the role of the human microbiome in carcinogenesis. Gut 68, 1624–1632 (2019).
Rao, B. C. et al. Human microbiome is a diagnostic biomarker in hepatocellular carcinoma. Hepatobiliary Pancreat. Dis. Int. 19, 109–115 (2020).
Kuntz, T. M. & Gilbert, J. A. Introducing the microbiome into precision medicine. Trends Pharm. Sci. 38, 81–91 (2017).
Rizkallah, M. R., Saad, R. & Aziz, R. K. The Human Microbiome Project, personalized medicine and the birth of phar macomicrobiomics. Curr. Pharm. Pers. Med. 8, 182–193 (2010).
